close

Agreements

Date: 2011-06-02

Type of information: Development agreement

Compound: in vitro PCR (Polymerase Chain Reaction) based EGFR companion diagnostic test

Company: Roche (Switzerland) Clovis Oncology (USA)

Therapeutic area: Cancer - Oncology

Type agreement:

development

Action mechanism:

Disease: non small cell lung cancer

Details:

Clovis Oncology and Roche have entered into an agreement to develop an in vitro PCR (Polymerase Chain Reaction) based companion diagnostic test. The goal is to identify activating epidermal growth factor receptor (EGFR) mutations in patients with non-small cell lung cancer (NSCLC), including the EGFR T790M mutation. This partnership with Roche will allow Clovis Oncology to incorporate a companion diagnostic during clinical and commercial development of CO-1686. This candidate is currently in pre-clinical development for advanced non small cell lung cancer (NSCLC) patients. CO-1686 has been designed to target and covalently bind to the activating and T790M mutant forms of EGFR. It does so while also sparing wild-type (normal) EGFR and may thus treat refractory NSCLC while minimizing dose-limiting side effects. CO-1686 was licensed to Clovis Oncology from Avila Therapeutics, Inc. The cobas EGFR mutation assay will run on the Roche cobas 4800 System, a platform designed to deliver new standards in laboratory testing efficiency and medically relevant diagnostic information. Cobas 4800 was recently approved in the US and all countries accepting a CE mark for use with the HPV test.

Financial terms:

Latest news:

Is general: Yes